NDOI Stock Overview
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Endo Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.05 |
| 52 Week High | US$29.75 |
| 52 Week Low | US$23.00 |
| Beta | 0 |
| 11 Month Change | 4.38% |
| 3 Month Change | -4.75% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| NDOI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.8% | -5.3% | -1.2% |
| 1Y | n/a | 8.7% | 30.4% |
Return vs Industry: Insufficient data to determine how NDOI performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NDOI performed against the US Market.
Price Volatility
| NDOI volatility | |
|---|---|
| NDOI Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NDOI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NDOI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,931 | Scott Hirsch | www.endo.com |
Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. It operates through four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment offers products for the treatment of conditions in urology, orthopedics, and endocrinology.
Endo Inc. Fundamentals Summary
| NDOI fundamental statistics | |
|---|---|
| Market cap | US$1.91b |
| Earnings (TTM) | US$3.37b |
| Revenue (TTM) | US$1.79b |
0.6x
P/E Ratio1.1x
P/S RatioIs NDOI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NDOI income statement (TTM) | |
|---|---|
| Revenue | US$1.79b |
| Cost of Revenue | US$850.31m |
| Gross Profit | US$940.06m |
| Other Expenses | -US$2.43b |
| Earnings | US$3.37b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 44.08 |
| Gross Margin | 52.51% |
| Net Profit Margin | 188.11% |
| Debt/Equity Ratio | 152.4% |
How did NDOI perform over the long term?
See historical performance and comparison